Raphael Pharmaceutical (RAPH) Cash & Equivalents Growth (1y) (2021 - 2025)
Raphael Pharmaceutical (RAPH) Cash & Equivalents Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | -39.02% |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 120.45% |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn | 12.78% |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | 50.32% |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | -32.64% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | 138.97% |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.52 Bn | 800.70 Mn | 37.30% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -12.11% |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 136.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 136.84% |
| Sep 30, 2025 | -92.50% |
| Jun 30, 2025 | -83.33% |
| Mar 31, 2025 | -82.58% |
| Dec 31, 2024 | -91.74% |
| Sep 30, 2024 | -86.62% |
| Jun 30, 2024 | 8.11% |
| Mar 31, 2024 | 655.26% |
| Dec 31, 2023 | -20.14% |
| Sep 30, 2023 | 221.51% |
| Jun 30, 2023 | -17.78% |
| Mar 31, 2023 | -53.09% |
| Dec 31, 2022 | 88.24% |
| Sep 30, 2022 | 151.35% |
| Dec 31, 2021 | 61.05% |